Introduction:
Generalized lymphadenopathy is commonly attributed to infectious causes
such as human immunodeficiency virus (HIV) infection, Epstein-Barr virus
(EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), human
herpesvirus 6 (HHV-6), tuberculosis (TB), syphilis, cat-scratch disease
caused by Bartonella henselae, or other parasitic and fungal infections.
Lymphadenopathy can also occur following recent immunization and is
usually transient requiring no further workup. Ho et al described that
less than 1.1% of individuals developed lymphadenopathy following
coronavirus disease 2019 (COVID-19) vaccination lasting on average
between 10 days to two months. It was often identified incidentally on
computed tomography (CT) scans, routine screening mammography, or
positron emission tomography scans, breast MRI, and ultrasounds. The
most common site for COVID-19 vaccine-associated lymphadenopathy is
usually axillary followed by supraclavicular and cervical
lymphadenopathy. [1] In the following report, we present a rare case
of metastatic prostate cancer diagnosed after initially presenting as
generalized lymphadenopathy following a COVID booster vaccination.